Kornimate/medical-research-clean huggingface dataset:
incidence, patient characteristics and outcome of myocarditis after covid-19 mrna vaccine

Conditions: Myocarditis

Summary: this study evaluates the incidence, patient characteristics and outcome of myocarditis after the covid-19 mrna vaccination in healthcare professionals.

considering previous reports of cardiovascular adverse events, passive surveillance might not identify all myocarditis/myopericarditis cases after covid-19 vaccination and it is possible that a mild/subclinical myocarditis might be much more prevalent in the population. this research project has three aims: first, provide novel insights regarding the incidence, patient characteristics and outcome of myocarditis. second, provide a safety net by active surveillance for myocarditis, allowing early initiation of appropriate therapy. third, provide reassurance to the public regarding myocarditis, as questions have been raised by critics of the pharmaceutical industry that phase iii studies performed by the pharmaceutical industry may have not appropriately captured adverse events. this study is screening persons undergoing the covid-19 mrna booster vaccination of possible development of myocarditis. this approach in detecting myocarditis would help early initiation of the right treatment under close monitoring of the clinical course. furthermore, this kind of study might also help understand the development of myocarditis and possibly the reasons for sex differences. myocarditis suspicion is raised when patients present symptoms of acute chest discomfort, myalgia, fever/chills, abnormal ecg, increased concentrations of high-sensitivity cardiac troponin t (hs-ctnt), possibly supported by signs of cardiac inflammation in cmri (myocardial oedema, myocardial/pericardial late gadolinium enhancement, pericardial effusion). since the study is performed on health care professionals working in the university hospital basel, it is able to monitor more closely the possible side effects of the mrna vaccination. consecutive individuals that received a covid-19 mrna vaccine booster and undergo a systematic approach to detect myocarditis at the university hospital basel will be included.

Eligibility criteria:
inclusion criteria: * individuals working at the university hospital basel, switzerland * informed consent available * 16-65 years old exclusion criteria: * refusal to participate at the study * cardiac events or cardiac surgery within 30 days prior to study (as these could result in prolonged hs-ctnt elevations and interfere with the diagnosis of myocarditis

Keywords: major adverse cardiac events (mace) covid-19 vaccination comirnaty (pfizer/biontech) mrna vaccine moderna mrna vaccine myopericarditis health care professionals covid-19 booster vaccination vaccination-induced myocarditis
pain measured by nrs and eeg in acute pulpitis

Conditions: Acute Pulpitis

Summary: the aim of the proposed study is to investigate and comprehensively understand pain perception in patients diagnosed with symptomatic acute pulpitis who are resistant to inferior alveolar nerve block (ianb). the study aims to achieve this by utilizing a dual approach that combines subjective self-reporting of pain intensity using the numeric rating scale (nrs) with objective neurophysiological assessment through brain wave analysis using electroencephalography (eeg). by integrating these two methods, the study seeks to explore potential correlations between self-reported pain scores and neural responses recorded through eeg, providing insights into the pain experience of this specific patient population. ultimately, the goal of the study is to enhance the understanding of pain perception mechanisms in individuals with symptomatic acute pulpitis resistant to ianb and potentially guide the development of more effective and personalized pain management strategies for these patients.


Eligibility criteria:
inclusion criteria: adults aged \[18-50 years\]. clinically diagnosed with symptomatic acute pulpitis based on dental examination and radiographic findings. demonstrates resistance to inferior alveolar nerve block (ianb). willing and able to provide informed consent to participate in the study. able to communicate effectively in the language used for study procedures. exclusion criteria: individuals with known neurological or psychiatric disorders affecting pain perception. pregnant individuals or those breastfeeding at the time of the study. history of severe allergies or adverse reactions to local anesthetics or eeg gel. presence of significant medical conditions that may contraindicate dental procedures or eeg recordings. individuals taking medications that could significantly affect pain perception (e.g., strong analgesics, sedatives). any contraindications for dental procedures or eeg recordings as determined by the study's dental and medical professionals. inability to understand and follow study instructions.

Keywords: acute pulpits electroencephalography numerical rate scale inferior alveolar nerve block
metadherin mrna expression in bladder cancer

Conditions: Bladder Cancer

Summary: the study aims to study alterations of mtdh gene expression in the serum of bladder cancer patients compared to control group to evaluate its role as a marker for diagnosis. ,to compare the diagnostic accuracy of mtdh with the previously used marker bladder cancer-specific antigen-1 (blca-1 in the serum of bladder cancer patients . and to study correlation between expression of the metadherin gene and serum level of blca-1, and clinical and histopathological staging in patients with bladder cancer

urinary bladder cancer (bc) is the ninth most common cancer worldwide. it is the fifth most common malignancy in males and seventeenth most common in females. in egypt, bladder cancer represents a massive health burden where it is one of the commonest cancers representing 6.9% in both sexes and 10.7% among men. its distribution is 8.8% in lower egypt, 14.2% in middle egypt and 12.6% in upper egypt.almost 50% of patients will experience recurrence of their disease within 4 years of their initial diagnosis.the prognosis of bladder cancer is poor as a result of highly invasive properties of tumour cells. the optimal treatment selection depends on early diagnosis as well as accurate staging and grading.currently there is a need for new molecular bio markers that can help clinicians to identify patients requiring early, aggressive treatment. metadherin (mtdh) is an oncogene known as astrocytic elevated gene-1(aeg-1).it was firstly identified in 2002 at fetal astrocytes of persons exposed to hiv-1 and then known as a vital oncogene mediating carcinogenesis,prognosis,invasion and cancer metastasis. aeg-1 expression is raised in bladder cancer tissues relative to normal tissues, and serves as a poor prognostic factor.

Eligibility criteria:
inclusion criteria: * males and females. * 30-80 years old. * patients with bladder cancer not receiving any treatment exclusion criteria: 1. patients taking chemotherapy or radiotherapy. 2. history of other malignancy. 3. history of autoimmune diseases.
total transfemoral branched endovascular thoracoabdominal aortic repair registry

Conditions: Aortic Aneurysm, Abdominal; Aortic Aneurysm, Thoracic

Summary: the purpose of the registry is to evaluate the peri-operative, short-, and mid- outcomes of endovascular treatment of thoracoabdominal aneurysms with multibranched endografts via total transfemoral approach for visceral vessels cannulation using steerable sheaths


Eligibility criteria:
inclusion criteria: * patient adult ( ≥18 years) of either sex, * patients who underwent a complex aortic procedure requiring a branched endograft via total transfemoral approach in the centers involved in the torch2 registry exclusion criteria: * patients who did not receive treatment via total transfemoral approach, * patient with bleeding diathesis or coagulopathy, * patients with active systemic or cutaneous infection or inflammation, * patients who are pregnant or lactating, * patient younger than 18 years of age. * absence of at least one imaging follow-up within the first post-operative year
anxiety and sexual malfunction functions in infertile pcos women

Conditions: Quality of Life

Summary: polycystic ovary syndrome (pcos) is a common hormonal disorder in females in reproductive age associated with signs and symptoms as amenorrhea or oligomenorrhea, obesity,infertility acne and hirsutism tism that mostly reduce self steem and having negative impact on physical and sexual quality of life , the management of signs and symptoms should result in improvement in the quality of life


Eligibility criteria:
inclusion criteria: - age:20-40 married infertile exclusion criteria: * any other diseases could affect quality of life
esophagogastric histopathology potentially guided patients younger than 50 years old to undergo colonoscopy earlier

Conditions: Colorectal Neoplasms

Summary: colorectal cancer (crc) is the third most diagnosed cancer worldwide and second leading cause of cancer death. most crcs arise from a polyp, developing through two major precursor lesion pathways: the traditional adenoma-carcinoma pathway, and the serrated neoplasia pathway. this provides opportunities to prevent cancer by removing its precursor lesions. crc screening efforts are directed toward removal of precancerous polyps with colonoscopy and detection of early-stage crc, which has been demonstrated to reduce crc incidence and mortality effectively, making crc one of the most preventable and treatable forms of cancer. current guidelines in china recommend starting crc screening uniformly at age 50 in average-risk individuals. however, a one-fits-all approach to determining crc screening starting age may be not conducive to personalized screening, especially in the developing countries with scarce health resources. the incidence of early-onset crc (crc diagnosed before the age of 50) has shown a continuous increasing trend worldwide, spurring the us preventive services task force to recommend initiating average-risk crc screening at age 45 instead of 50. furthermore, different populations may benefit from even earlier screening, and crc incidence may differ on the basis of population characteristics and crc risk factors. for individuals younger than 50 years old, earlier screening based on risk factors may address this concern. previous studies have recommended earlier starting age of crc screening combined with risk factors such as but not limited to sex, age, family history, lifestyle and comorbidity. some upper gastrointestinal diseases have also been reported to be associated with an increased risk of colorectal neoplasms, which may be related to the destruction of gastric acid barrier function and long-term use of pump proton inhibitors. compared with colonoscopy examination, individuals were more willing to undergo esophagogastroduodenoscopy (egd) examination for gastric cancer screening, especially among the younger, potentially utilizing the egd to guide earlier colonoscopies for patients at increased risk. therefore, this study was aimed to investigate the association between esophagogastric histopathology and colorectal neoplasms in patients under the age of 50 and whether these risks factor could be combined with to guide earlier crc screening.


Eligibility criteria:
inclusion criteria: patients younger than 50 years old who underwent gastroscopy and colonoscopy simultaneously. exclusion criteria: 1. patients without a good bowel preparation (boston bowel preparation scale \[bbps\] score ≥ 6); 2. incomplete gastroscopy or colonoscopy examinations; 3. partial or total gastrointestinal resection; 4. patients who have been diagnosed with gastrointestinal cancer before endoscopy; 5. hereditary polyposis, including peutz-jeghers syndrome, and familial adenomatous polyposis; 6. a history of inflammatory bowel diseases.
extension study for patients who have participated in a bmn 701 study

Conditions: Pompe Disease

Summary: this is a phase 2 open-label, multiple dose study of bmn 701 administered by iv infusion every 2 weeks (qow) to patients with late-onset pompe disease.


Eligibility criteria:
inclusion criteria: * have completed a prior bmn 701 clinical development study; * have provided written informed consent after the nature of the study has been explained prior to performance of any study-related procedures. minors may participate as long as they provide written assent after the nature of the study has been explained to them and after their parent, or legal guardian has provided written informed consent, prior to the performance of any study-related procedures; * have been diagnosed with late-onset pompe disease, based on the entry criteria of a prior bmn 701 study; * if sexually active, be willing to use 2 known effective methods of contraception from screening until 4 months after the last dose of study-drug; * if female, and not considered to be of childbearing potential, be at least 2 years post-menopausal, or have had tubal ligation at least 1 year prior to screening, or have had a total hysterectomy; * if female, and of childbearing potential, have a negative pregnancy test during the screening period and at the baseline visit, and be willing to have additional pregnancy tests during the study; * have the ability to comply with the protocol requirements, in the opinion of the investigator. exclusion criteria: * have received any experimental or approved therapy for pompe disease, other than bmn 701, subsequent to completion of a bmn 701 study and prior to entry into pom-002; * have received, or are anticipated to receive, any investigational medication, other than bmn 701, within 30 days prior to the first dose of study-drug; * are breastfeeding at screening or planning to become pregnant (self or partner) at any time during the study; * have a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the patient's ability to comply with the protocol requirements or compromise the patient's well being or safety.
disseminated tumour cells (dtc) in left sided colorectal cancer (lscc).

Conditions: Colorectal Cancer; Bone Marrow Tumor Cell Infiltration

Summary: two metaanalyses of studies on the prognostic significance of circulating cancer cells in colorectal cancer indicated, that the presence of circulating tumour cells (ctc) in the peripheral blood is the negative prognostic factor. however there is no sufficient evidence that disseminated tumour cells (dtc) in the bone marrow of the colorectal cancer patients influence the prognosis. there is the evidence that right-sided and left- sided cancers may have different biology and different prognosis. therefore in this study the investigators concentrated on the left colon and rectum locations with the locally advanced cancer being the main area of interest. the aim of this study was to analyse the relation of dtc with the tumor characteristics, cancer progression and survival in left sided colorectal cancer.

a group of 91 colorectal patients treated in a single institution was involved into the study. only the patients with tumors located in the rectum or left side colon were included. the term left colon was defined as the left 1/3 of transverse colon and all the colon parts distally from this point. none of the colon cancer patients received preoperative chemotherapy, while 5 of the rectal cancer patients received preoperative radiotherapy and two preoperative radiochemotherapy. there were 42 women and 49 men, the mean age 64,7 (sd - standard deviation 10,2). the bone marrow biopsy was performed on the day of surgery after the induction of general anesthesia from posterior superior iliac spine. the 5ml sample of the bone marrow was collected to plastic tubes containing ethylenediaminetetraacetic (edta). patients received postoperative chemotherapy if indicated, regardless of their dtc status. all the patients were followed up at least for 5 years or until death. the incidence of dtc was not related to the depth of infiltration (t feature) being similar in t1-2 and t4 patients. there was no statistically significant difference between the incidence of dtc in n- and n+ patients. the 5 years survival rate for the dtc patients was 59,5% while for the dtc negative patients was 53%.

Eligibility criteria:
inclusion criteria: * age \> 18 years * histologically proven left-sided colorectal cancer * signed informed consent exclusion criteria: * synchronous right sided colon cancer * history of other neoplasm * inability to understand and sign informed consent
effect of transdermal magnesium chloride on quality of life in patients with fibromyalgia

Conditions: Fibromyalgia; Fibromyalgia Syndrome

Summary: in this pilot study we propose to gather preliminary data on whether transdermal magnesium chloride can improve quality of life in patients with fibromyalgia. forty women with fibromyalgia will be enrolled in this study. participants will be asked to apply a topical solution of magnesium chloride on their extremities 3 times daily for 28 consecutive days. three questionnaires measuring quality of life will be administered at baseline, at 2 weeks, and at 4 weeks (end of study).

fibromyalgia is a chronic pain syndrome with no known etiology. fibromyalgia is generally diagnosed in patients reporting widespread musculoskeletal pain, and tenderness. in addition to widespread pain, fibromyalgia is also characterized by chronic fatigue, depression, sleep disturbances, and poor concentration. it has been reported that approximately 3.5% of women and 0.5% of men in the united states suffer from fibromyalgia. while the primary cause of fibromyalgia remains unclear, a growing body of evidence indicates that the widespread pain associated with fibromyalgia is due to abnormalities in the central nervous system. the pain threshold, both mechanical and thermal, in fibromyalgia sufferers are lowered such that it requires a lesser than normal stimulus to elicit pain. recent reports suggest that fibromyalgia is an oxidative stress disorder and deficiency in trace elements and antioxidants play an important role in the development of fibromyalgia. magnesium is a trace element that is important for many metabolic functions. it affects cell membrane permeability and electrical activity. the similarity in the clinical symptoms of fibromyalgia and magnesium deficiency along with the histopathological findings of tender points (such as hypoxia and adenosine triphosphate deficiency) raises the possibility that magnesium may play a role in fibromyalgia etiopathogenesis. in this pilot study we propose to explore the feasibility and ease of 2 times a day application of a topical solution to the arms and legs. we will also gather preliminary data on whether transdermal magnesium chloride can improve quality of life in women with fibromyalgia.

Eligibility criteria:
inclusion criteria: * patients diagnosed with fibromyalgia at mayo clinic rochester's fibromyalgia clinic * postmenopausal women (no menstrual period for 1 year or more) * women age 40-70 that have had a hysterectomy * willing to travel to mayo clinic rochester for the initial instruction visit * able to apply the transdermal magnesium chloride as directed * able to complete the questionnaires and daily diary * able and willing to give informed consent * able to speak, write and understand english exclusion criteria: * patients on dialysis * individuals who decline to participate in the study * diagnoses of bipolar disorder, schizophrenia or dementia * patients with myasthenia gravis and myasthenic syndromes * patients on magnesium supplements

Keywords: fibromyalgia fibromyalgia syndrome magnesium chloride transdermal magnesium chloride
safety study to evaluate ly3114062 in participants with inflammatory arthritis

Conditions: Inflammatory Arthritis

Summary: the main purpose of this study is to learn more about the safety of ly3114062 and to find out how well it is tolerated in participants with an inflammatory arthritis. the study will also investigate how the body processes the drug and how the drug affects inflammatory arthritis. the study is expected to last about 3 months.


Eligibility criteria:
inclusion criteria: * signs or symptoms of an inflammatory arthritis for a duration of at least 8 weeks at screening. * presence of at least 3 out of 66 swollen joints at screening and baseline, as determined by the swollen joint count assessment forms. exclusion criteria: * synthetic disease-modifying antirheumatic drugs dmard use as follows: * any treatment with tofacitinib within 28 days prior to baseline or planned treatment with tofacitinib during the study; * treatment with other synthetic dmards (eg, hydroxychloroquine, methothrexate, leflunomide, sulfasalazine, and gold salts) at an unstable dose within 28 days prior to baseline or if the dose of drug is planned to be changed during the study. * previous treatment with marketed biologic dmards as follows: * etanercept, adalimumab, or anakinra \<4 weeks prior to baseline; * infliximab, certolizumab pegol, golimumab, abatacept, or tocilizumab \<8 weeks prior to baseline; * rituximab \<12 months prior to baseline note: other biologic agents for indications other than an inflammatory arthritis may be allowed after discussion with the sponsor * treatment with \>10 mg/day, or unstable dose, of oral prednisone or equivalent within 28 days prior to baseline. * confirmed or suspected septic arthritis, crystal arthropathy, systemic lupus erythematosus, reactive arthritis, or certain other rheumatic conditions.

Keywords: antibody tumor necrosis factor alpha interleukin-17
efficacy of elidel cream on erosive oral lichen planus

Conditions: Lichen Planus, Oral

Summary: the purpose of this study is to investigate whether topical applied pimecrolimus will lead to improvement of erosive oral lichen planus. this effect will be monitored by reduction of erosive mucosal area and reduction of patient's pain symptoms.

oral lichen planus is a mucosal inflammatory disease of unknown origin. it can be very painful especially if erosions appear on the oral mucosa. in this study the efficacy of pimecrolimus compared to placebo in treatment of erosive oral lichen planus will be investigated. to this end the subjective pain and the amount of affected mucosa will be monitored before and after treatment.

Eligibility criteria:
inclusion criteria: * clinically and histologically confirmed diagnosis of erosive oral lichen planus * spontaneous or meal related oral pain * no topical therapy 2 weeks prior to study start * no systemic therapy 4 weeks prior to study start * signed informed consent exclusion criteria: * pregnant or breast-feeding women * known allergy to macrolide antibiotics * known current active malignant disease or in patient's history * known immunodeficiency or hiv infection * participation at another clinical trial within the last 6 months